1. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study.
- Author
-
Zeng QL, Yu ZJ, Lv J, Zhang HX, Wang B, Dong XP, Chen ZM, Cui GL, and Ji F
- Subjects
- Antiviral Agents therapeutic use, Drug Therapy, Combination, Female, Fluorenes therapeutic use, Genotype, Hepacivirus genetics, Humans, Infant, Newborn, Pregnancy, Pregnant Women, Treatment Outcome, Hepatitis C, Chronic, Sofosbuvir therapeutic use
- Abstract
Data on sofosbuvir-based therapy for pregnant women and infants with severe chronic hepatitis C (CHC) are lacking. Two late pregnant women and one female infant with severe CHC were enrolled for treatment. Pregnant Women 1 and 2 and Infant 3 were 30, 33, and 1.2 years old, respectively; the gestational ages of pregnant Women 1 and 2 were 31 and 26 weeks, respectively. Notably, pregnant Women 1 and 2 and Infant 3 had hepatitis C virus (HCV) RNA levels of 139 000, 198 000, and 8 450 000 IU/ml; alanine aminotransferase levels of 420, 781, and 220 U/L; and received sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and sofosbuvir/ledipasvir for 12 weeks, respectively. All three patients were safely cured with favorable tolerance, and two newborns were both breastfeeding and were consistently negative for the anti-HCV antibody during the 1-year follow-up after birth. Additionally, two newborns and Infant 3 had normal growth parameters during the follow-up year one. In conclusion, this case series study found that sofosbuvir-based therapy for pregnant women and infants with severe CHC is safe and effective. The data may fill the gap and provide evidence of the use of sofosbuvir-based therapy as a reference when similar severe CHC situations are encountered during clinical practice., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF